Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03574584 · ClinicalTrials.gov registry record · Phase 1
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT03574584 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 37 participants.
The verdict
NCT03574584, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body. Participants will get semaglutide and either NNC0165-1562 or "dummy" medicine -which treatment participants get is decided by chance. Participants will get 2 injections per week for 5 months. A study nurse at the clinic will inject the medicine with a thin needle in a skin fold in the stomach. The study will last for about 7 months. Participants will have 27 visits to the clinic.
Interventions
- DRUG Semaglutide
- DRUG NNC0165-1562
- DRUG Placebo (NNC0165-1562)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-06-18 |
| Est. Completion | 2019-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03574584
The ClinicalTrials.gov registry entry for NCT03574584 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Semaglutide is the first listed.
NCT03574584 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03574584 about?
NCT03574584 is a clinical study titled "A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese". The study is investigating new medicines for weight control in people with high body weight. The study looks at how the study medicines work in the body. Participants will get semaglutide and either NNC0165-1562 or "dummy" medicine -which treatment participants get is decided by chance. Participants...
What is the current status of trial NCT03574584?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2018-06-18. Estimated completion is 2019-07-27.
What interventions are being tested in trial NCT03574584?
The interventions under investigation include: Semaglutide (DRUG), NNC0165-1562 (DRUG), Placebo (NNC0165-1562) (DRUG).
Who is sponsoring clinical trial NCT03574584?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.